Phase 1b Study of Pirtobrutinib, Plerixafor, and Lisocabtagene Maraleucel in relapsed/refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and mantle cell lymphoma

Key Points

• Treatment with pirtobrutinib shows encouraging results for patients with lymphoma, enhancing remission rates.
• A combination of pirtobrutinib, plerixafor, and lisocabtagene maraleucel was utilized to target resistant cases.
• This observational analysis focused on relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.
• Further clinical trials are needed to validate these findings and improve treatment options for lymphomas.